Current status of diagnosis and clinical treatment on co-existent pulmonary tuberculosis and lung cancer

doi:10.19983/j.issn.2096-8493.2024054

Abstract

Abstract:

Lung cancer and pulmonary tuberculosis are two major respiratory diseases that seriously endanger human health. Each disease causes about 1.6 million deaths per year worldwide. Particularly in developing countries, there are high incidences of both diseases. Epidemiological evidence suggests that pulmonary tuberculosis increases the risk of lung cancer. The clinical symptoms of pulmonary tuberculosis and lung cancer are too similar, the co-existence and mutual influence of the two diseases make it difficult to diagnose and treat them, which brings a huge burden to patients. This paper reviews the pathogenesis, diagnosis and treatment of lung cancer complicated with pulmonary tuberculosis.

Key words: Tuberculosis,pulmonary, Carcinoma,non-small-cell lung, Diagnosis,differentia

CLC Number:

R521
R734

Yang Hongjie, Qi Fei, Zhang Hongmei, Wu Hongbo, Hu Aimin, Zhang Tongmei. Current status of diagnosis and clinical treatment on co-existent pulmonary tuberculosis and lung cancer[J]. Journal of Tuberculosis and Lung Disease , 2024, 5(3): 273-278. doi: 10.19983/j.issn.2096-8493.2024054

References 53

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1):15-19. doi:10.19983/j.issn.2096-8493.2023006.
[2]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48. doi:10.3322/caac.21763.
[3]	Brenner AV, Wang Z, Kleinerman RA, et al. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol, 2001, 30(1): 118-124. doi:10.1093/ije/30.1.118. pmid: 11171871
[4]	Shirai R, Ohnishi T, Miyamoto J, et al. Two cases of multiple primary cancer involving the lung with old pulmonary tuberculosis. Nihon Kokyuki Gakkai Zasshi, 2000, 38(3): 211-216. pmid: 10846404
[5]	孙大力, 刘春英, 白树明. 肺结核合并肺癌病因及临床病理分析. 黑龙江医学, 2001, 25(9): 666.
[6]	左美蓉. 老年肺结核合并肺癌20例临床分析. 临床肺科杂志, 2004, 9(1): 28. doi:10.3969/j.issn.1009-6663.2004.01.044.
[7]	Kim HR, Hwang SS, Ro YK, et al. Solid-organ malignancy as a risk factor for tuberculosis. Respirology, 2008, 13(3): 413-419. doi:10.1111/j.1440-1843.2008.01282.x.
[8]	廖小阳. 肺结核合并肺癌的原因初探. 中南医学科学杂志, 2004, 32(1): 123-124. doi:10.3969/j.issn.2095-1116.2004.01.047.
[9]	刘心, 夏淑珍, 姜振东. 肺结核并存肺癌38例临床分析. 中国现代医生, 2008, 46(9): 59-60. doi:10.3969/j.issn.1673-9701.2008.09.029.
[10]	Hwang IK, Paik SS, Lee SH. Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma. Cancer Res Treat, 2019, 51(1): 158-168. doi:10.4143/crt.2018.084. pmid: 29621876
[11]	Cao S, Li J, Lu J, et al. Mycobacterium tuberculosis antigens repress Th 1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway. Cell Death Dis, 2019, 10(2): 44. doi:10.1038/s41419-018-1237-y.
[12]	Zemanova M, Pirker R, Petruzelka L, et al. Care of patients with non-small-cell lung cancer stage Ⅲ-the Central European real-world experience. Radiol Oncol, 2020, 54(2): 209-220. doi:10.2478/raon-2020-0026. pmid: 32463394
[13]	Zhou Y, Cui Z, Zhou X, et al. The presence of old pulmonary tuberculosis is an independent prognostic factor for squamous cell lung cancer survival. J Cardiothorac Surg, 2013, 8: 123. doi:10.1186/1749-8090-8-123. pmid: 23647947
[14]	赵宇. 肺结核并发肺癌的临床分析. 中国实用医刊, 2011, 38(21): 107-108. doi:10.3760/cma.j.issn.1674-4756.2011.21.064.
[15]	Kim YI, Goo JM, Kim HY, et al. Coexisting bronchogenic carcinoma and pulmonary tuberculosis in the same lobe: radiologic findings and clinical significance. Korean J Radiol, 2001, 2(3): 138-144. doi:10.3348/kjr.2001.2.3.138. pmid: 11752984
[16]	Palanivel J, Sounderrajan V, Thangam T, et al. Latent Tuberculosis: Challenges in Diagnosis and Treatment, Perspectives, and the Crucial Role of Biomarkers. Curr Microbiol, 2023, 80(12): 392. doi:10.1007/s00284-023-03491-x.
[17]	Miller WT. Tuberculosis in the 1990’s. Radiol Clin North Am, 1994, 32(4): 649-661.
[18]	吕岩, 谢汝明, 周新华, 等. 肺结核与肺癌并存的CT影像研究. 中华放射学杂志, 2013, 47(1): 8-12. doi:10.3760/cma.j.issn.1005-1201.2013.01.003.
[19]	李永波, 王志永, 张志飞, 等. 周围型肺腺癌误诊为肺结核球的CT表现及误诊原因分析. 解放军预防医学杂志, 2016, 42(S2): 10-11.
[20]	Jain SK, Andronikou S, Goussard P, et al. Advanced imaging tools for childhood tuberculosis: potential applications and research needs. Lancet Infect Dis, 2020, 20(11): e289-e297. doi:10.1016/s1473-3099(20)30177-8.
[21]	张慧. 重组结核分枝杆菌ESAT6-CFP10变态反应原的临床效用的评价及其相关统计方法研究. 北京: 中国人民解放军空军军医大学, 2020.
[22]	Galal El-Din M, Sobh E, Adawy Z, et al. Diagnostic utility of gene X-pert in the diagnosis of tuberculous pleural effusion. Infect Dis (Lond), 2019, 51(3): 227-229. doi:10.1080/23744235.2018.1532105.
[23]	Rauf F, Anderson KS, Labaer J. Autoantibodies in Early Detection of Breast Cancer. Cancer Epidemiol Biomarkers Prev, 2020, 29(12): 2475-2485. doi:10.1158/1055-9965.Epi-20-0331.
[24]	Massion PP, Healey GF, Peek LJ, et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol, 2017, 12(3): 578-584. doi:10.1016/j.jtho.2016.08.143. pmid: 27615397
[25]	Liu Y, Wang F, Zhang QC, et al. Value of virtual bronchoscopic navigation and transbronchial ultrasound-guided sheath-guided exploration in diagnosis of peripheral lung cancer. World J Clin Cases, 2020, 8(16): 3450-3457. doi:10.12998/wjcc.v8.i16.3450. pmid: 32913851
[26]	潘蕾, 薄丽艳, 李王平, 等. 虚拟支气管镜导航联合经支气管超声导向鞘引导技术与常规支气管镜诊断周围型肺癌的临床研究. 中华肺部疾病杂志(电子版), 2017, 10(2): 124-129. doi:10.3877/cma.j.issn.1674-6902.2017.02.002.
[27]	阮佳星, 徐志晓, 潘凌云, 等. 影像引导经胸壁肺穿刺术诊断肺结节的研究进展. 中国呼吸与危重监护杂志, 2021, 20(9): 677-680. doi:10.7507/1671-6205.202102026.
[28]	Andrade JR, Rocha RD, Falsarella PM, et al. CT-guided percutaneous core needle biopsy of pulmonary nodules smaller than 2 cm: technical aspects and factors influencing accuracy. J Bras Pneumol, 2018, 44(4): 307-314. doi:10.1590/s1806-37562017000000259. pmid: 30328929
[29]	Choi JW, Park CM, Goo JM, et al. C-arm cone-beam CT-guided percutaneous transthoracic needle biopsy of small (≤20mm) lung nodules: diagnostic accuracy and complications in 161 patients. AJR Am J Roentgenol, 2012, 199(3): W322-330. doi:10.2214/ajr.11.7576.
[30]	Li GC, Fu YF, Cao W, et al. Computed tomography-guided percutaneous cutting needle biopsy for small (≤ 20mm) lung nodules. Medicine (Baltimore), 2017, 96(46): e8703. doi:10.1097/md.0000000000008703.
[31]	Choi SH, Chae EJ, Kim JE, et al. Percutaneous CT-guided aspiration and core biopsy of pulmonary nodules smaller than 1 cm: analysis of outcomes of 305 procedures from a tertiary referral center. AJR Am J Roentgenol, 2013, 201(5): 964-970. doi:10.2214/ajr.12.10156.
[32]	Hwang EJ, Kim H, Park CM, et al. Cone beam computed tomography virtual navigation-guided transthoracic biopsy of small (≤1 cm) pulmonary nodules: impact of nodule visibility during real-time fluoroscopy. Br J Radiol, 2018, 91(1087): 20170805. doi:10.1259/bjr.20170805.
[33]	Portela De Oliveira E, Souza CA, Inacio JR, et al. Imaging-guided Percutaneous Biopsy of Nodules ≤1cm: Study of Diagnostic Performance and Risk Factors Associated With Biopsy Failure. J Thorac Imaging, 2020, 35(2): 123-128. doi:10.1097/rti.0000000000000427.
[34]	Guibert N, Pradines A, Favre G, et al. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev, 2020, 29(155):190052. doi:10.1183/16000617.0052-2019.
[35]	Liang W, Chen Z, Li C, et al. Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test. J Clin Invest, 2021, 131(10):e145973. doi:10.1172/jci145973.
[36]	Hawkins S, Wang H, Liu Y, et al. Predicting Malignant Nodules from Screening CT Scans. J Thorac Oncol, 2016, 11(12): 2120-2128. doi:10.1016/j.jtho.2016.07.002. pmid: 27422797
[37]	Ardila D, Kiraly AP, Bharadwaj S, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med, 2019, 25(6): 954-961. doi:10.1038/s41591-019-0447-x. pmid: 31110349
[38]	Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl_4): iv1-iv21. doi:10.1093/annonc/mdx222.
[39]	洪建军, 路丽苹, 金晓萍. 以患者需求为基础的肺结核综合治疗管理模式应用效果评价. 中国全科医学, 2013, 16(5): 543-545. doi:10.3969/j.issn.1007-9572.2013.02.059.
[40]	Evman S, Baysungur V, Alpay L, et al. Management and Surgical Outcomes of Concurrent Tuberculosis and Lung Cancer. Thorac Cardiovasc Surg, 2017, 65(7): 542-545. doi:10.1055/s-0036-1583167. pmid: 27111500
[41]	Ho JC, Leung CC. Management of co-existent tuberculosis and lung cancer. Lung Cancer, 2018, 122: 83-87. doi:10.1016/j.lungcan.2018.05.030.
[42]	Kim DK, Lee SW, Yoo CG, et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest, 2005, 128(4): 2218-2222. doi:10.1378/chest.128.4.2218. pmid: 16236877
[43]	Ye MF, Su S, Huang ZH, et al. Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis. Ann Transl Med, 2020, 8(18): 1143. doi:10.21037/atm-20-5964.
[44]	Chai M, Shi Q. The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis. BMC Cancer, 2020, 20(1): 1121. doi:10.1186/s12885-020-07622-6.
[45]	Zhang SZ, Zhu XD, Feng LH, et al. PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma. Exp Hematol Oncol, 2021, 10(1): 25. doi:10.1186/s40164-021-00218-1.
[46]	Shi J, Li J, Wang Q, et al. The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. Transl Lung Cancer Res, 2021, 10(10): 3929-3942. doi:10.21037/tlcr-21-524.
[47]	Burotto M, Manasanch EE, Wilkerson J, et al. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist, 2015, 20(4): 400-410. doi:10.1634/theoncologist.2014-0154. pmid: 25795635
[48]	Sgambato A, Casaluce F, Maione P, et al. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS 1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther, 2018, 18(1): 71-80. doi:10.1080/14737140.2018.1412260.
[49]	Luo YH, Wu CH, Wu WS, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol, 2012, 7(2): 299-305. doi:10.1097/JTO.0b013e31823c588d.
[50]	Lee HY, Kim JW, Yeo CD. A case of tuberculosis reactivation suspected of cancer progression during oral tyrosine kinase inhibitor treatment in a patient diagnosed as non-small cell lung cancer. J Thorac Dis, 2017, 9(8): E709-E713. doi:10.21037/jtd.2017.07.31.
[51]	Halleux CM, Falzon D, Merle C, et al. The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis. Eur Respir J, 2018, 51(3):1701643. doi:10.1183/13993003.01643-2017.
[52]	Zarredar H, Ansarin K, Baradaran B, et al. Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology. Cancer Invest, 2018, 36(1): 37-58. doi:10.1080/07357907.2017.1416393. pmid: 29336624
[53]	Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol, 2008, 23(2): 192-202. doi:10.1111/j.1440-1746.2007.05207.x.